Obicetrapib–ezetimibe combination therapy: a novel oral strategy for enhanced lipid lowering
Cardiovascular Research · 14.08.2026 · 122 (11) · 1409-1411
DOI: 10.1093/cvr/cvag138 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Research, online erschienen am 14.08.2026. Verfasst von Mitra Chitsazan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Iran University of Medical Sciences, Tehran, Iran. Die Arbeit nennt 13 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Medicine, Iran University of Medical Sciences, Tehran, Iran.
- Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.
- Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
ORCID-Profile: Mandana Chitsazan
Zitieren
APA
Chitsazan, M., Chitsazan, M., & Cannon, C. P. (2026). Obicetrapib–ezetimibe combination therapy: a novel oral strategy for enhanced lipid lowering. Cardiovascular Research, 122(11), 1409-1411. https://doi.org/10.1093/cvr/cvag138
Vancouver
Chitsazan M, Chitsazan M, Cannon CP. Obicetrapib–ezetimibe combination therapy: a novel oral strategy for enhanced lipid lowering. Cardiovascular Research. 2026;122(11):1409-1411. doi:10.1093/cvr/cvag138
BibTeX
@article{Chitsazan2026,
author = {Chitsazan, Mitra and Chitsazan, Mandana and Cannon, Christopher P},
title = {Obicetrapib–ezetimibe combination therapy: a novel oral strategy for enhanced lipid lowering},
journal = {Cardiovascular Research},
year = {2026},
volume = {122},
number = {11},
pages = {1409--1411},
doi = {10.1093/cvr/cvag138}
}
EUVIMED